HRP20130800T1 - Opioid receptor modulators - Google Patents

Opioid receptor modulators

Info

Publication number
HRP20130800T1
HRP20130800T1 HRP20130800TT HRP20130800T HRP20130800T1 HR P20130800 T1 HRP20130800 T1 HR P20130800T1 HR P20130800T T HRP20130800T T HR P20130800TT HR P20130800 T HRP20130800 T HR P20130800T HR P20130800 T1 HRP20130800 T1 HR P20130800T1
Authority
HR
Croatia
Prior art keywords
opioid receptor
receptor modulators
synthesis
directed
formula
Prior art date
Application number
HRP20130800TT
Other languages
English (en)
Inventor
Henry J. Breslin
Chaozhong Cai
Wei He
Robert W. Kavash
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20130800(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20130800T1 publication Critical patent/HRP20130800T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/417Imidazole-alkylamines, e.g. histamine, phentolamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Amplitude Modulation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Eye Examination Apparatus (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Amplifiers (AREA)
  • Hydrogenated Pyridines (AREA)
HRP20130800TT 2004-03-15 2013-08-22 Opioid receptor modulators HRP20130800T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55334204P 2004-03-15 2004-03-15

Publications (1)

Publication Number Publication Date
HRP20130800T1 true HRP20130800T1 (en) 2013-09-30

Family

ID=34962827

Family Applications (4)

Application Number Title Priority Date Filing Date
HR20110694T HRP20110694T1 (hr) 2004-03-15 2011-09-28 Novi spojevi kao modulatori opioidnog receptora
HRP20130800TT HRP20130800T1 (en) 2004-03-15 2013-08-22 Opioid receptor modulators
HRP20150305TT HRP20150305T1 (hr) 2004-03-15 2015-03-18 Postupak za pripravu intermedijera spojeva korisnih kao modulatori opioid receptora
HRP20161331TT HRP20161331T1 (hr) 2004-03-15 2016-10-12 Modulatori opioidnih receptora

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HR20110694T HRP20110694T1 (hr) 2004-03-15 2011-09-28 Novi spojevi kao modulatori opioidnog receptora

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20150305TT HRP20150305T1 (hr) 2004-03-15 2015-03-18 Postupak za pripravu intermedijera spojeva korisnih kao modulatori opioid receptora
HRP20161331TT HRP20161331T1 (hr) 2004-03-15 2016-10-12 Modulatori opioidnih receptora

Country Status (36)

Country Link
US (8) US7741356B2 (hr)
EP (5) EP3112352B1 (hr)
JP (1) JP4778954B2 (hr)
KR (1) KR101166342B1 (hr)
CN (2) CN102786476B (hr)
AR (2) AR048269A1 (hr)
AT (1) ATE516274T1 (hr)
AU (1) AU2005224091B2 (hr)
BR (1) BRPI0508820B8 (hr)
CA (1) CA2560047C (hr)
CR (1) CR8655A (hr)
CY (3) CY1111927T1 (hr)
DK (5) DK2573068T3 (hr)
EC (1) ECSP066856A (hr)
ES (5) ES2705077T3 (hr)
HK (4) HK1099016A1 (hr)
HR (4) HRP20110694T1 (hr)
HU (2) HUE029852T2 (hr)
IL (3) IL178040A (hr)
LT (2) LT2653465T (hr)
LU (1) LUC00007I2 (hr)
ME (3) ME02540B (hr)
MX (1) MXPA06010642A (hr)
MY (1) MY146972A (hr)
NL (1) NL300865I2 (hr)
NO (3) NO338203B1 (hr)
NZ (1) NZ549842A (hr)
PH (1) PH12012501640B1 (hr)
PL (4) PL2653465T3 (hr)
PT (4) PT2653465T (hr)
RS (4) RS54199B1 (hr)
SI (4) SI2573068T1 (hr)
TW (1) TWI361069B (hr)
UA (1) UA86053C2 (hr)
WO (1) WO2005090315A1 (hr)
ZA (1) ZA200608587B (hr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
DK2573068T3 (en) 2004-03-15 2015-02-16 Janssen Pharmaceutica Nv Process for the preparation of intermediates of compounds useful as opioid receptor modulators
EA013261B1 (ru) 2004-05-14 2010-04-30 Янссен Фармацевтика, Н.В. Опиоидные соединения, замещенные карбоксамидогруппой
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
MX2007011412A (es) * 2005-03-14 2008-02-22 Johnson & Johnson Procedimiento para la preparacion de moduladores de opioide.
EP1981854B1 (en) * 2005-12-14 2011-06-01 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
CN101336229B (zh) 2005-12-23 2012-06-13 西兰岛药物有限公司 改性的拟赖氨酸化合物
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
DK2468724T3 (en) 2006-12-21 2016-02-22 Zealand Pharma As Synthesis of pyrrolidine compounds
SG185941A1 (en) 2007-07-09 2012-12-28 Janssen Pharmaceutica Nv Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
TWI468375B (zh) * 2008-10-27 2015-01-11 Janssen Pharmaceutica Nv 製備經保護之l-丙胺酸衍生物之方法
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP5198220B2 (ja) * 2008-11-13 2013-05-15 東ソ−・エフテック株式会社 アミノ酸誘導体の製造方法
BRPI1006897A2 (pt) 2009-07-06 2015-09-08 Akebia Therapeutics Inc compostos, composições e métodos de prevenção da metástase de células cancerosas.
EP2524912A1 (en) 2011-05-16 2012-11-21 Bionomics Limited Amine derivatives
EP2709985B1 (en) 2011-05-16 2017-10-04 Bionomics Limited Amine derivatives as potassium channel blockers
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
EP2970133B1 (en) * 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
MX2015012850A (es) 2013-03-14 2016-06-24 Epizyme Inc Inhibidores de la arginina metiltransferasa y usos de los mismos.
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
US10702498B2 (en) 2015-07-09 2020-07-07 The Regents Of The University Of California MU opioid receptor modulators
EP3325450A1 (en) 2015-07-23 2018-05-30 Teva Pharmaceuticals International GmbH Solid state forms of eluxadoline
CN108026032B (zh) * 2015-09-11 2020-09-29 株式会社钟化 光学活性4-氨基甲酰基-2,6-二甲基苯基丙氨酸衍生物的制造方法
JP6959924B2 (ja) 2015-09-23 2021-11-05 エアーピオ ファーマシューティカルズ, インコーポレイテッド Tie−2の活性化物質を用いる眼内圧を処置する方法
CN105250232B (zh) * 2015-09-29 2018-08-14 江苏汇智知识产权服务有限公司 一种伊卢多啉肠溶片及其制备方法
WO2017114446A1 (zh) * 2015-12-31 2017-07-06 苏州晶云药物科技有限公司 艾沙度林的新晶型及其制备方法
CN107129444B (zh) * 2016-02-29 2018-08-31 尚科生物医药(上海)有限公司 (s)-2-叔丁氧羰基氨基-3-(4-氨甲酰基-2,6-二甲基苯基)丙酸制备方法
EP3272741A1 (en) 2016-07-21 2018-01-24 Euticals S.P.A. New stable solvate crystalline forms of eluxadoline
CN105777584B (zh) * 2016-03-28 2018-01-02 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
CN105693554B (zh) * 2016-04-06 2017-08-08 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
WO2017191650A1 (en) * 2016-05-03 2017-11-09 Msn Laboratories Private Limited Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino]methyl-2-methoxybenzoic acid and its polymorphs thereof
MA45184A (fr) * 2016-05-30 2019-04-10 Sun Pharmaceutical Ind Ltd Procédé de préparation de l'éluxadoline .
US10822308B2 (en) * 2016-06-23 2020-11-03 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018020450A2 (en) 2016-07-28 2018-02-01 Lupin Limited Process for the preparation of eluxadoline
CZ2016548A3 (cs) 2016-09-07 2018-03-14 Zentiva, K.S. Pevné formy eluxadolinu
WO2018047131A1 (en) * 2016-09-09 2018-03-15 Sun Pharmaceutical Industries Limited Amorphous eluxadoline
US10479769B2 (en) 2016-09-20 2019-11-19 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018138272A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline form and process for the preparation thereof
EP3573958A1 (en) 2017-01-27 2019-12-04 Quimica Sintetica, S.A. Eluxadoline crystalline forms and processes for their preparation
ES2870106T3 (es) 2017-05-05 2021-10-26 Zealand Pharma As Moduladores de la comunicación intercelular de uniones comunicantes y su uso para el tratamiento de la enfermedad del ojo diabético
WO2019008604A1 (en) 2017-07-07 2019-01-10 Cipla Limited NEW FORMS OF MU-OPIOID RECEPTOR AGONIST
WO2019144805A1 (zh) * 2018-01-25 2019-08-01 四川科伦博泰生物医药股份有限公司 取代的苯乙胺化合物及其制备方法和用途
WO2019197274A1 (en) 2018-04-09 2019-10-17 Quimica Sintetica, S. A. Process for the preparation of opioid modulators
US20210251964A1 (en) 2018-08-20 2021-08-19 Allergan Holdings Unlimited Company Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
DK3659433T3 (da) * 2018-11-30 2021-04-19 Phytobiotics Futterzusatzstoffe Gmbh System til analyse af billeder af dyrs afføring
CN111377832A (zh) * 2018-12-27 2020-07-07 江苏联昇化学有限公司 一种伊卢多啉中间体制备的新方法
AU2020264969A1 (en) 2019-04-29 2021-12-09 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
WO2021198780A1 (en) 2020-03-30 2021-10-07 Allergan Holdings Unlimited Company Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
AU2021318923A1 (en) * 2020-07-28 2023-03-09 Jazz Pharmaceuticals Ireland Limited Chiral synthesis of fused bicyclic Raf inhibitors
US11850319B2 (en) 2020-09-29 2023-12-26 Abl Ip Holding Llc Techniques for directing ultraviolet energy towards a moving surface
US11896728B2 (en) 2020-09-29 2024-02-13 Abl Ip Holding Llc Techniques for directing ultraviolet energy towards a moving surface
CN114163348A (zh) * 2020-11-27 2022-03-11 成都泰蓉生物科技有限公司 一种氨酰基取代的l-苯丙氨酸的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD142804A3 (de) * 1977-11-07 1980-07-16 Wagner Guenter Verfahren zur herstellung von na-alkyl-bzw.na-aryl-sulfonylierten omega-amidinophenyl-alpha-aminoalkylcarbonsaeureamiden
US4879398A (en) * 1987-12-31 1989-11-07 Monsanto Company Process for producing 2,6-disubstituted tyrosine
SE9402880D0 (sv) 1994-08-30 1994-08-30 Astra Ab New peptide derivatives
EP0805816B1 (en) 1995-01-27 2004-07-28 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
JP3950170B2 (ja) 1995-04-13 2007-07-25 アベンティス・ファーマスーティカルズ・インコーポレイテッド タキキニン受容体アンタゴニスト活性を有する新規な置換されたピペラジン誘導体
AU6772996A (en) 1995-08-21 1997-03-12 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues
AU7710596A (en) 1995-11-29 1997-06-19 Nihon Nohyaku Co., Ltd. Phenylalanine derivatives, optically active substances, salts or coordination compounds thereof, and their use as fungicides
US5792760A (en) 1997-04-23 1998-08-11 Eli Lilly And Company Bisindoles as tachykinin receptor antagonists
IT1304898B1 (it) 1998-09-08 2001-04-05 Menarini Ricerche Spa Prodotti con caratteristiche basiche aventi attivita' antagonista sulrecettore nk-1 e loro impiego in preparazioni farmaceutiche
ES2206139T3 (es) * 1999-05-28 2004-05-16 Pfizer Products Inc. Derivados de 3-(3-hidrofenil)-3-amino-propionamida.
FR2796643B1 (fr) 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB0021419D0 (en) 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
US20020072017A1 (en) * 2000-10-19 2002-06-13 Hudnall Phillip Montgomery Stabilized p-phenylenediamine-type photographic color developers in free base form
EE200300168A (et) 2000-10-30 2003-06-16 Janssen Pharmaceutica N.V. Tripeptidüülpeptidaasi inhibiitorid, nende valmistamine ja kasutamine ravimina ning neid sisaldav farmatseutiline kompositsioon
PL367967A1 (en) 2001-10-15 2005-03-07 Janssen Pharmaceutica N.V. Novel substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists
US7041681B2 (en) 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
DK2573068T3 (en) * 2004-03-15 2015-02-16 Janssen Pharmaceutica Nv Process for the preparation of intermediates of compounds useful as opioid receptor modulators
US7282507B2 (en) 2004-05-03 2007-10-16 Janssen Pharmaceutica N.V. Indole derivatives as selective androgen receptor modulators (SARMS)
MX2007011412A (es) * 2005-03-14 2008-02-22 Johnson & Johnson Procedimiento para la preparacion de moduladores de opioide.

Also Published As

Publication number Publication date
PT2573068E (pt) 2015-04-27
MXPA06010642A (es) 2007-03-26
JP2007529527A (ja) 2007-10-25
US8344011B2 (en) 2013-01-01
CR8655A (es) 2008-09-09
PT2298744E (pt) 2013-09-12
CN1950342A (zh) 2007-04-18
HK1184432A1 (en) 2014-01-24
KR20060131983A (ko) 2006-12-20
LTC1725537I2 (lt) 2018-02-26
US10213415B2 (en) 2019-02-26
CN1950342B (zh) 2012-09-26
SI1725537T1 (sl) 2011-11-30
BRPI0508820A (pt) 2007-08-07
US20180325870A1 (en) 2018-11-15
PL2298744T3 (pl) 2013-11-29
EP2298744B1 (en) 2013-06-26
EP2298744A2 (en) 2011-03-23
DK3112352T3 (en) 2019-01-28
ES2705077T3 (es) 2019-03-21
IL229444A0 (en) 2013-12-31
NO20064660L (no) 2006-12-14
US7741356B2 (en) 2010-06-22
ECSP066856A (es) 2006-11-24
PT1725537E (pt) 2011-09-08
EP1725537A1 (en) 2006-11-29
US20100324051A1 (en) 2010-12-23
US8609709B2 (en) 2013-12-17
PH12012501640A1 (en) 2015-10-05
DK2298744T3 (da) 2013-09-02
HUS1700010I1 (hu) 2017-03-28
HRP20161331T1 (hr) 2016-12-30
CY1111927T1 (el) 2015-11-04
HK1155726A1 (en) 2012-05-25
PL2573068T3 (pl) 2015-06-30
US20160030393A1 (en) 2016-02-04
AU2005224091A1 (en) 2005-09-29
MY146972A (en) 2012-10-15
EP2653465A1 (en) 2013-10-23
LUC00007I2 (hr) 2017-05-02
US9205076B2 (en) 2015-12-08
NZ549842A (en) 2010-10-29
CA2560047A1 (en) 2005-09-29
NO20160916A1 (no) 2006-12-14
DK1725537T3 (da) 2011-10-31
HK1105967A1 (en) 2008-02-29
ES2367576T3 (es) 2011-11-04
UA86053C2 (ru) 2009-03-25
ME02540B (me) 2017-02-20
SI2653465T1 (sl) 2016-10-28
PL1725537T3 (pl) 2011-12-30
EP3112352A1 (en) 2017-01-04
EP3112352B1 (en) 2018-11-21
HRP20150305T1 (hr) 2015-04-24
DK2653465T3 (da) 2016-08-22
NO2017007I1 (no) 2017-02-23
ME01601B (me) 2014-09-20
JP4778954B2 (ja) 2011-09-21
TW200539876A (en) 2005-12-16
US20140039024A1 (en) 2014-02-06
PH12012501640B1 (en) 2015-10-05
IL178040A0 (en) 2006-12-31
SI2298744T1 (sl) 2013-10-30
RS51995B (en) 2012-04-30
AR048269A1 (es) 2006-04-12
IL224908A (en) 2015-07-30
US8772325B2 (en) 2014-07-08
AR095848A2 (es) 2015-11-18
US9700542B2 (en) 2017-07-11
LTPA2017005I1 (lt) 2017-03-27
IL229444A (en) 2017-03-30
EP2298744A3 (en) 2011-08-10
EP2573068A1 (en) 2013-03-27
LUC00007I1 (hr) 2017-03-03
CA2560047C (en) 2013-12-24
HUE029852T2 (en) 2017-04-28
HRP20110694T1 (hr) 2011-12-31
CY2017008I1 (el) 2017-11-14
RS55122B1 (sr) 2016-12-30
TWI361069B (en) 2012-04-01
US20080096888A1 (en) 2008-04-24
WO2005090315A1 (en) 2005-09-29
ZA200608587B (en) 2008-06-25
ES2533176T3 (es) 2015-04-08
PL2653465T3 (pl) 2017-01-31
RS52933B (en) 2014-02-28
IL178040A (en) 2013-12-31
US20130090478A1 (en) 2013-04-11
SI2573068T1 (sl) 2015-03-31
CY1118096T1 (el) 2017-06-28
HK1099016A1 (en) 2007-08-03
NL300865I2 (nl) 2020-08-17
CY2017008I2 (el) 2017-11-14
US7786158B2 (en) 2010-08-31
ME02221B (me) 2016-02-20
ES2596434T3 (es) 2017-01-09
NO2017007I2 (no) 2017-02-23
PT2653465T (pt) 2016-09-22
AU2005224091B2 (en) 2012-02-02
EP2573068B1 (en) 2014-12-31
BRPI0508820B8 (pt) 2022-11-29
DK2573068T3 (en) 2015-02-16
NO338203B1 (no) 2016-08-08
US20050203143A1 (en) 2005-09-15
NL300865I1 (nl) 2017-03-14
EP1725537B1 (en) 2011-07-13
KR101166342B1 (ko) 2012-07-18
RS54199B1 (en) 2015-12-31
ES2428008T3 (es) 2013-11-05
LT2653465T (lt) 2016-09-12
CN102786476B (zh) 2017-01-18
EP2653465B1 (en) 2016-07-13
CN102786476A (zh) 2012-11-21
US20140256779A1 (en) 2014-09-11
BRPI0508820B1 (pt) 2018-04-10
ATE516274T1 (de) 2011-07-15
EP2573068B9 (en) 2015-08-26

Similar Documents

Publication Publication Date Title
HRP20130800T1 (en) Opioid receptor modulators
NO20084783L (no) Syntese av acylaminoalkenylenamider nyttige som substans P antagonister
HU0400405D0 (en) Novel compounds
HK1159064A1 (en) Processes for the preparation of aminosulfone compounds
SE0201635D0 (sv) Novel compounds
MY152183A (en) Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
MX2009005461A (es) N-oxidos de analogos de 4,5-epoxi-morfinano.
JO2947B1 (en) Compounds corresponding to cyclopamine
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
CY1108880T1 (el) Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα
PL1831202T3 (pl) Pochodne pirolidyniowe jako receptory M3 muskarynowe
MX2007007446A (es) Procesos para la produccion de 4-aminoquinazolinas.
PT1509517E (pt) Nova síntese de irbesartan
WO2007082262A3 (en) Novel compounds
TW200738713A (en) Diazepinoquinolines, synthesis thereof, and intermediates thereto
SI1723140T1 (sl) Postopek za pripravo inhibitorjev triptaze
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands
TW200640870A (en) Novel compounds
GT200500224A (es) Proceso para la sìntesis de indoles n-alquilados c-2, c-3 sustituidos ùtiles como inhibidores de cpla2
NO20076161L (no) Fremgangsmater for fremstilling av 4-bifenylazetidin-2-oner
TW200616624A (en) 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity
GB0320738D0 (en) Novel process
SG155231A1 (en) Process for synthesis of dialkoxyorganoboranes
IL162071A0 (en) Process for synthesis of dinitrotetraoxadiazaisowurzitane (dtiw)